The Elipse Balloon in DietSpotlight
DietSpotlight recently wrote a comprehensive article on popular weight loss therapies and procedures. Here’s what they had to say about the Elipse Balloon: “The Elipse Balloon is the world’s first and only procedure-less intra-gastric balloon for weight loss. The balloon is swallowed in a capsule and filled with liquid in a 20-minute office visit. While in the stomach, the balloon is designed to help people feel full and encourage portion control. After four months, the balloon spontaneously opens, empties, and passes out of the body. The Elipse Balloon does not require surgery, endoscopy, or anesthesia for either placement or removal.”…
Allurion’s Shantanu Gaur on Jim Cramer’s Mad Money
Allurion Technologies founder discusses his company’s non-invasive ‘balloon’ pill that helps treat obesity from CNBC.
Why have healthcare companies and physicians failed to solve the obesity epidemic?
In a recent guest post on MedCity News, Dr. Shantanu Gaur asks why healthcare companies and physicians have failed to solve the obesity epidemic. The answer has much more to do with how we treat the consumer than how we think about technology. Check out the article here!
Three Things The Tech Industry Has Right And The Medical Industry Has Wrong
Dr. Shantanu Gaur recently authored a guest post on TechCrunch on what the medtech industry can learn from the tech industry. Namely, 1) be open with data; 2) create an experience, not just a product; and 3) treat users as participants, not just purchasers. Check out the article here!
Allurion Technologies: A Treatment for Obesity That’s Easy to Swallow
Allurion Technologies and the Elipse Balloon were featured in the March issue of Medtech Strategist in an article entitled “Allurion Technologies: A Treatment for Obesity That’s Easy to Swallow”. Thank you to Mary Stuart for a very thoughtful profile of our company and device. Click here to access the article!
Elipse Gastric Balloon Featured in WebMD
Allurion’s Elipse was recently featured in WebMD’s Future of Health series in an article entitled “The Next Generation of Weight Loss.” Click here to see the story!
Allurion co-founders featured in LeadDoc
Allurion Technologies co-founders Shantanu Gaur and Samuel Levy were featured in the latest edition of Lead Doc – the online journal for emerging physician leaders. Click here to read their story!
Patient Preference for Weight Loss Devices
The US Food and Drug Administration (FDA) recently published an article in Surgical Endoscopy that reports results of a survey conducted on patient preference for weight loss devices. The survey quantifies the risk-benefit analysis many patients conduct before deciding on a weight loss therapy. This research is part of a laudable, ongoing effort at FDA to incorporate patient preference in regulatory decision-making. Moreover, the research provides very useful quantitative data to support FDA’s risk-benefit paradigm for evaluating new weight loss devices. In fact, this approach was instrumental in the recent approval of the Enteromedics VBLOC device. While the device failed…
Data Presented on New Gastric Balloons for Weight Loss
Louise Gagnon recently interviewed Allurion’s Chief Scientific Officer Shantanu Gaur for her story in General Surgery News on the Elipse Balloon. The article highlights Allurion’s presentation at this year’s International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress and underscores the key differences between the Elipse Balloon and all other gastric balloons in development. Here’s an excerpt: In an interview with General Surgery News, Dr. Gaur pointed out that the Elipse has distinct advantages over other intragastric balloons. “The difference with our device, compared to other intragastric balloons, is that it does not require endoscopy or anesthesia,” Dr. Gaur said. Click…
A balloon for obesity: an option between medication and surgery?
The Elipse Balloon was recently covered by Melissa Healy of the LA Times in an article entitled A balloon for obesity: an option between medication and surgery? Here is an excerpt: For many struggling with obesity, taking one of the newly approved prescription medications for weight loss (marketed as Qsymia, Belviq and Contrave) feels like climbing a mountain with a walking cane — it’s a little help, but not enough. And bariatric surgery — a permanent replumbing of the intestinal tract that is expensive and carries the risks of major surgery — feels like a bit too much help. Could a water balloon…